Payment overview · 2025
General Payments
$3,648.66
149 reported records · 23 companies
Healthcare provider profile · identity verified
Kompal Parmar, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LUBBOCK, TX · NPI 1710270988
Verified facts
What the public records show
CMS Open Payments records show Kompal Parmar, M.D. received $3,648.66 in general payments during 2025 across 149 reported records.
ABBVIE INC. accounted for 10.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess, Mounjaro, Ozempic, Trelegy Ellipta, Tymlos.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Paxlovid by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Tymlos by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $396.93 | 10.9% | 17 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $339.33 | 9.3% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $329.55 | 9.0% | 15 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $303.50 | 8.3% | 18 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $258.75 | 7.1% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $237.51 | 6.5% | 12 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $206.50 | 5.7% | 9 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $195.40 | 5.4% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $178.67 | 4.9% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $159.56 | 4.4% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $156.11 | 4.3% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $154.15 | 4.2% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $147.58 | 4.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $122.79 | 3.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $122.14 | 3.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $77.92 | 2.1% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $70.65 | 1.9% | 4 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $69.12 | 1.9% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $44.66 | 1.2% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $32.28 | 0.9% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.71 | 0.5% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $15.09 | 0.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.76 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,648.66 | 149 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $272.37 | 9 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $258.75 | 13 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $242.25 | 9 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $213.88 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $212.73 | 10 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $206.50 | 9 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $178.67 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $171.05 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $159.56 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $156.11 | 13 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $154.15 | 4 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $130.35 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $130.35 | 1 | 2025 |
Source payment records
|
|||||
| ANNOVERA Normalized: annovera |
Drug | MAYNE PHARMA COMMERCIAL LLC | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $122.79 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $122.14 | 2 | 2025 |
Source payment records
|
|||||
| BIJUVA Normalized: bijuva |
Drug | MAYNE PHARMA COMMERCIAL LLC | $95.58 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $93.45 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $89.94 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $89.66 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $87.26 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $83.24 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $77.92 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $77.92 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $70.65 | 4 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $69.12 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $55.44 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $55.44 | 4 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $44.66 | 2 | 2025 |
Source payment records
|
|||||
| Vyrsa V1 Normalized: vyrsa v1 |
Device | Globus Medical, Inc. | $32.28 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.36 | 3 | 2025 |
Source payment records
|
|||||
| LO LOESTRIN FE Normalized: lo loestrin fe |
Drug | ABBVIE INC. | $25.51 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $24.78 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $24.35 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $15.09 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $12.00 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $9.39 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $9.39 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 24 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 73 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 153 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 119 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 73 | exact normalized | Medicare Part D |
| Tymlos tymlos |
2025 | Tymlos | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
24 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
73 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
73 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
85 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
153 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
61 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
44 | 44 |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 787 | 172 |
| Atorvastatin Calcium | Atorvastatin Calcium | 444 | 114 |
| Lisinopril | Lisinopril | 438 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 389 | 97 |
| Omeprazole | Omeprazole | 336 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 330 | 95 |
| Potassium Chloride | Potassium Chloride | 327 | 85 |
| Metformin Hcl | Metformin Hcl | 309 | 84 |
| Losartan Potassium | Losartan Potassium | 296 | 85 |
| Alendronate Sodium | Alendronate Sodium | 269 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 259 | 77 |
| Gabapentin | Gabapentin | 247 | 65 |
| Naproxen | Naproxen | 247 | 74 |
| Montelukast Sodium | Montelukast Sodium | 245 | 51 |
| Simvastatin | Simvastatin | 244 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 239 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 236 | 66 |
| Tramadol Hcl | Tramadol Hcl | 235 | 66 |
| Escitalopram Oxalate | Escitalopram Oxalate | 196 | 54 |
| Allopurinol | Allopurinol | 189 | 53 |
| Furosemide | Furosemide | 187 | 42 |
| Tizanidine Hcl | Tizanidine Hcl | 186 | 60 |
| Azithromycin | Azithromycin | 182 | 157 |
| Fluticasone Propionate | Fluticasone Propionate | 181 | 56 |
| Mounjaro | Tirzepatide | 153 | 25 |
| Meloxicam | Meloxicam | 147 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 143 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 139 | 34 |
| Prednisone | Prednisone | 137 | 114 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 53 |
| Pravastatin Sodium | Pravastatin Sodium | 133 | 31 |
| Sertraline Hcl | Sertraline Hcl | 133 | 42 |
| Carvedilol | Carvedilol | 124 | 36 |
| Celecoxib | Celecoxib | 121 | 36 |
| Ozempic | Semaglutide | 119 | 25 |
| Alprazolam | Alprazolam | 113 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 107 | 31 |
| Famotidine | Famotidine | 103 | 16 |
| Trazodone Hcl | Trazodone Hcl | 103 | 29 |
| Lactulose | Lactulose | 94 | 15 |
| Metformin Hcl Er | Metformin Hcl | 93 | 21 |
| Glipizide Er | Glipizide | 92 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 91 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 90 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 87 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 86 | 26 |
| Jardiance | Empagliflozin | 85 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 83 | 76 |
| Pregabalin | Pregabalin | 78 | 31 |
| Donepezil Hcl | Donepezil Hcl | 77 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 22 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 76 | 36 |
| Ketoconazole | Ketoconazole | 76 | 39 |
| Cephalexin | Cephalexin | 75 | 52 |
| Linzess | Linaclotide | 73 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 73 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 73 | 51 |
| Fenofibrate | Fenofibrate Nanocrystallized | 68 | 11 |
| Clonazepam | Clonazepam | 67 | suppressed |
| Amoxicillin | Amoxicillin | 66 | 61 |
| Spironolactone | Spironolactone | 64 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 24 |
| Buspirone Hcl | Buspirone Hcl | 61 | 21 |
| Eliquis | Apixaban | 61 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 13 |
| Meclizine Hcl | Meclizine Hcl | 59 | 26 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 14 |
| Bupropion Xl | Bupropion Hcl | 58 | 13 |
| Estradiol | Estradiol | 58 | 21 |
| Levetiracetam | Levetiracetam | 46 | suppressed |
| Ezetimibe | Ezetimibe | 45 | 16 |
| Januvia | Sitagliptin Phosphate | 45 | 12 |
| Telmisartan | Telmisartan | 45 | 16 |
| Paxlovid | Nirmatrelvir/Ritonavir | 44 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Carbamazepine | Carbamazepine | 42 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | suppressed |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Methylprednisolone | Methylprednisolone | 40 | 37 |
| Ondansetron Odt | Ondansetron | 40 | 32 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 37 |
| Temazepam | Temazepam | 39 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 37 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 37 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 35 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 34 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Valsartan | Valsartan | 34 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | 11 |
| Ibuprofen | Ibuprofen | 33 | 13 |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 19 |
| Baclofen | Baclofen | 27 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Levemir Flexpen | Insulin Detemir | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Creon | Lipase/Protease/Amylase | 24 | 12 |
| Olanzapine | Olanzapine | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 21 |
| Nyamyc | Nystatin | 22 | suppressed |
| Nystatin | Nystatin | 22 | 20 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | 12 |
| Finasteride | Finasteride | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 12 |
| Metronidazole | Metronidazole | 20 | 19 |
| Azelastine Hcl | Azelastine Hcl | 19 | 12 |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | 14 |
| Methylphenidate Er | Methylphenidate Hcl | 18 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 17 |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Nortrel | Norethindrone-Ethin. Estradiol | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Ofloxacin | Ofloxacin | 15 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Tymlos | Abaloparatide | 15 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Ciclopirox | Ciclopirox | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Sprintec | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 12 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Primidone | Primidone | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,648.66 · 149 records | ABBVIE INC. | AIRSUPRA, ANNOVERA, AREXVY, AUSTEDO XR, Auvelity, BIJUVA, CAPLYTA, CREON, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Dexcom G6 Transmitter, EVENITY, GEMTESA, Kerendia, Korlym, LINZESS, LO LOESTRIN FE, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Ohtuvayre, Ozempic, PENMENVY, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, Symbravo, TRELEGY ELLIPTA, TRINTELLIX, Tymlos, UBRELVY, VRAYLAR, Vyrsa V1, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error